BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21128060)

  • 1. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
    Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Taku K; Fukutomi A; Onozawa Y
    Gastric Cancer; 2010 Nov; 13(4):245-50. PubMed ID: 21128060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
    Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
    Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
    Imamura H; Kishimoto T; Takiuchi H; Kimura Y; Morimoto T; Imano M; Iijima S; Yamashita K; Maruyama K; Otsuji T; Kurokawa Y; Furukawa H
    J Chemother; 2014 Feb; 26(1):57-61. PubMed ID: 24090674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    Lee JL; Kang YK; Kang HJ; Lee KH; Zang DY; Ryoo BY; Kim JG; Park SR; Kang WK; Shin DB; Ryu MH; Chang HM; Kim TW; Baek JH; Min YJ
    Br J Cancer; 2008 Aug; 99(4):584-90. PubMed ID: 18665164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
    Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2012 Jan; 15(1):76-82. PubMed ID: 21717091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
    Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
    Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
    Nishiyama O; Taniguchi H; Kondoh Y; Takada K; Baba K; Saito H; Sugino Y; Yamamoto M; Ogasawara T; Kondo M; Imaizumi K; Hasegawa Y; Suzuki R; Shimokata K;
    Anticancer Drugs; 2011 Sep; 22(8):811-6. PubMed ID: 21317767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
    Arai K; Iwasaki Y; Kimura Y; Takahashi K; Yamaguchi T; Honma S; Takahashi T
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1297-301. PubMed ID: 14518409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
    Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Fukutomi A; Todaka A; Taniguchi H; Onozawa Y; Taku K
    Int J Clin Oncol; 2013 Feb; 18(1):10-6. PubMed ID: 22020563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
    Takahashi I; Kakeji Y; Emi Y; Sakurai M; Yonemura Y; Kimura Y; Maehara Y
    Gastric Cancer; 2003; 6 Suppl 1():28-33. PubMed ID: 12775017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
    Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
    Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
    Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
    Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.